|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Dana-Farber Cancer Institute National Cancer Institute (NCI) |
| Information provided by: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00004034 |
Purpose
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. It is not yet known which treatment regimen is more effective for acute lymphoblastic leukemia.
PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of combination chemotherapy and radiation therapy in treating children who have acute lymphoblastic leukemia.
| Condition | Intervention | Phase |
|
Cardiac Toxicity Leukemia Quality of Life |
Drug: asparaginase Drug: cytarabine Drug: dexrazoxane hydrochloride Drug: doxorubicin hydrochloride Drug: leucovorin calcium Drug: mercaptopurine Drug: methotrexate Drug: methylprednisolone Drug: prednisolone Drug: prednisone Drug: therapeutic hydrocortisone Drug: vincristine Procedure: quality-of-life assessment Procedure: radiation therapy |
Phase III |
| MedlinePlus related topics: | Cancer Leukemia, Childhood |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized |
| Official Title: | Treatment of Childhood Acute Lymphoblastic Leukemia: Grant Application Title: Erwinia Asparaginase in Childhood Acute Leukemia |
Eligibility
| Ages Eligible for Study: | 1 Year to 17 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS: Histologically or cytologically proven acute lymphoblastic leukemia (ALL) No mature B-cell ALL (i.e., surface immunoglobulin present and L3 morphology) Standard risk disease at diagnosis defined as: 1 to 9 years at diagnosis Highest pretreatment WBC less than 50,000/mm3 No blasts on CSF cytospin No T-cell markers on lymphoblasts No anterior mediastinal mass No cranial nerve palsy High risk disease defined as any patient who fails to meet all standard risk criteria at either diagnosis or at end of induction No t(8;14) (q24;q32), t(8;22), or t(2;8) T-cell surface markers and t(8;14) (q24;q11) allowed Investigational Window eligibility: At least 30 days since prior steroid therapy No concurrent emergent mediastinal radiotherapy or intubation No septic shock No concurrent intracranial hemorrhage No clinical evidence of CNS or lung leukostasis Bilirubin less than 1.4 mg/dL
PATIENT CHARACTERISTICS: Age: 1 to 17 Performance status: Not specified Hematopoietic: See Disease Characteristics Hepatic: See Disease Characteristics Renal: Not specified Other: HIV negative
PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy Chemotherapy: No prior chemotherapy Endocrine therapy: See Disease Characteristics No more than 1 week of steroids Radiotherapy: See Disease Characteristics Prior emergent radiotherapy to the mediastinum allowed Surgery: Not specified Other: Prior leukapheresis or exchange transfusion allowed, but must be completed before study
Contacts and Locations| United States, Louisiana | |||||
| Ochsner Clinic | |||||
| New Orleans, Louisiana, United States, 70121 | |||||
| United States, Maine | |||||
| Maine Children's Cancer Program | |||||
| Portland, Maine, United States, 04101 | |||||
| United States, Massachusetts | |||||
| Dana-Farber Cancer Institute | |||||
| Boston, Massachusetts, United States, 02115 | |||||
| United States, New York | |||||
| Mount Sinai School of Medicine | |||||
| New York, New York, United States, 10029 | |||||
| University of Rochester Cancer Center | |||||
| Rochester, New York, United States, 14642 | |||||
| Canada, Ontario | |||||
| McMaster Division | |||||
| Hamilton, Ontario, Canada, L8N 3Z5 | |||||
| Canada, Quebec | |||||
| Hopital Sainte Justine | |||||
| Montreal, Quebec, Canada, H3T 1C5 | |||||
| Laval University Medical Center | |||||
| Sainte-Foy, Quebec, Canada, G1V 4G2 | |||||
| Puerto Rico | |||||
| San Jorge Childrens Hospital | |||||
| Santurce, Puerto Rico, 00912 | |||||
| Dana-Farber Cancer Institute |
| National Cancer Institute (NCI) |
| Study Chair: | Stephen E. Sallan, MD | Dana-Farber Cancer Institute |
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
| Study ID Numbers: | CDR0000066202, DFCI-95001, DFCI-FDR001197, NCI-G99-1651 |
| First Received: | December 10, 1999 |
| Last Updated: | May 23, 2008 |
| ClinicalTrials.gov Identifier: | NCT00004034 |
| Health Authority: | United States: Federal Government |
|
|
|
|
|